Literature DB >> 9819838

Statistical issues for HIV surrogate endpoints: point/counterpoint. An NIAID workshop.

J M Albert1, J P Ioannidis, P Reichelderfer, B Conway, R W Coombs, L Crane, R Demasi, D O Dixon, P Flandre, M D Hughes, L A Kalish, K Larntz, D Lin, I C Marschner, A Muñoz, J Murray, J Neaton, C Pettinelli, W Rida, J M Taylor, S L Welles.   

Abstract

This paper summarizes the proceedings of an NIAID-sponsored workshop on statistical issues for HIV surrogate endpoints. The workshop brought together statisticians and clinicians in an attempt to shed light on some unresolved issues in the use of HIV laboratory markers (such as HIV RNA and CD4+ cell counts) in the design and analysis of clinical studies and in patient management. Utilizing a debate format, the workshop explored a series of specific questions dealing with the relationship between markers and clinical endpoints, and the choice of endpoints and methods of analysis in clinical studies. This paper provides the position statements from the two debaters on each issue. Consensus conclusions, based on the presentations and discussion, are outlined. While not providing final answers, we hope that these discussions have helped clarify a number of issues, and will stimulate further consideration of some of the highlighted problems. These issues will be critical in the proper assessment and use of future therapies for HIV disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9819838

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  5 in total

1.  Considerations for Endpoint Selection When Designing HIV Clinical Trials.

Authors:  Katherine Huppler Hullsiek; Birgit Grund
Journal:  Curr Infect Dis Rep       Date:  2012-02       Impact factor: 3.725

2.  Evaluating the Proportion of Treatment Effect Explained by a Continuous Surrogate Marker in Logistic or Probit Regression Models.

Authors:  Jie Huang; Bin Huang
Journal:  Stat Biopharm Res       Date:  2010-05-01       Impact factor: 1.452

3.  Semiparametric regression analysis of partly interval-censored failure time data with application to an AIDS clinical trial.

Authors:  Qingning Zhou; Yanqing Sun; Peter B Gilbert
Journal:  Stat Med       Date:  2021-05-26       Impact factor: 2.373

Review 4.  Efavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Joanna Kryst; Paweł Kawalec; Andrzej Pilc
Journal:  PLoS One       Date:  2015-05-01       Impact factor: 3.240

Review 5.  Nevirapine-based regimens in HIV-infected antiretroviral-naive patients: systematic review and meta-analysis of randomized controlled trials.

Authors:  Paweł Kawalec; Joanna Kryst; Alicja Mikrut; Andrzej Pilc
Journal:  PLoS One       Date:  2013-10-07       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.